ArticleArchives of medical science : AMS2018
The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention.
Article in Archives of medical science : AMS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The alteration of bile acids and gut microbiota is associated with intestinal barrier dysfunction and inflammaging in human.Frontiers in aging · 2026Article
- Pathogenic mechanism of intestinal microbiota involved in Guillain-Barré syndrome and withArchives of medical science : AMS · 2025Article
- Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Review
- Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers.Journal of physiology and biochemistry · 2023Review
- Nanoparticles alleviate non-alcoholic steatohepatitis via ER stress sensor-mediated intestinal barrier damage and gut dysbiosis.Frontiers in microbiology · 2023Article
- Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss.Archives of medical science : AMS · 2022Article
- Relationships Between Diurnal Changes of Tongue Coating Microbiota and Intestinal Microbiota.Frontiers in cellular and infection microbiology · 2022Article
- Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.Frontiers in nutrition · 2022Review
- Low-Grade Endotoxemia and Thrombosis in COVID-19.Clinical and translational gastroenterology · 2021Article
- Antioxidative activity of probiotics.Archives of medical science : AMS · 2021Article
- EphrinA1/EphA2 Promotes Epithelial Hyperpermeability Involving in Lipopolysaccharide-induced Intestinal Barrier Dysfunction.Journal of neurogastroenterology and motility · 2020Article
- Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.BMC complementary medicine and therapies · 2020Article
- Hemofiltration in Patients with Severe Acute Pancreatitis (Review).Sovremennye tekhnologii v meditsine · 2020Review
- The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.Diseases (Basel, Switzerland) · 2019Review
- The intestinal barrier: a fundamental role in health and disease.Expert review of gastroenterology & hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, close links between intestinal microbiota and host metabolism have been recognized. Intestinal bacteria can participate in the extraction of calories from food, and circulation of bacterial products, in particular lipopolysaccharides (LPS), is responsible for the "metabolic endotoxemia", which contributes to insulin resistance and its complications, such as non-alcoholic fatty liver disease (NAFLD). Indeed, qualitative and quantitative intestinal dysbiotic changes have been clearly documented in NAFLD patients, and several mechanisms by which the intestinal microbiota can directly promote liver fat deposition, inflammation and fibrosis have also been described. Consistently, although with some differences concerning type and proportion of results, experimental and clinical studies are quite concordant in demonstrating beneficial effects of probiotic and/or prebiotic therapy in NAFLD. Although some physiopathological bases have been produced, major doubts still remain concerning how and when to intervene. Indeed, most of the available works were performed with mixtures of probiotics and/or prebiotics, and a baseline assessment of dysbiosis aimed at selecting the best candidates for treatment and predicting response has not been performed in any of the clinical studies in NAFLD. While future research is expected to solve these issues, the particularly favorable safety profile suggests that probiotic/prebiotic therapy could already be "tested" in NAFLD patients on an individual basis, at least once all the measures recommended by the latest guidelines have failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.